Wockhardt

Pharmaceuticals firm Wockhardt Ltd on Monday reported a consolidated profit after tax of Rs 107 crore for the first quarter ended June 30, mainly due to strong revenue growth. The company had posted a consolidated net loss of Rs 108 crore in the corresponding period of the last fiscal, Wockhardt Ltd said in a regulatory filing. Its consolidated revenue from operations in the first quarter stood at Rs 929 crore against Rs 738 crore a year ago, it added. Total expenses in the quarter under review were higher at Rs 844 crore compared to Rs 770 crore in the year-ago period, it said.

Wockhardt's FDA-approved Zaynich marks a breakthrough in India's pharmaceutical innovation, offering a new weapon against antimicrobial resistance

For decades, India excelled at making affordable generic medicines. But creating a brand-new drug from scratch remained a rare achievement. Now, Wockhardt has made history with Zaynich

Once-a-day injectable antibiotic aimed at treatment beyond hospitals through outpatient centres

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of R&D

Stocks to Watch, June 2: L&T, Anant Raj, Ola Electric, Paytm, Alkem Labs among shares to remain on investors' and traders' radar today

Novel antibiotic to be launched in India around the same time; company to commercialise product on its own in US

Wockhardt recently received USFDA approval for Zaynich (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections, including pyelonephritis, in adults.

The buying on the counter came after the company received approval from the CDSCO for the import and marketing of Zaynich Zidebactam/Cefepime

Mayank Jain, market analyst at Share.Market by PhonePe believes that the long-term trend for Ola Electric can change from 'Bearish to Bullish' if the stock manages to sustain above ₹40 consistently.

Kunal Kamble, sr. technical research analyst at Bonanza, has recommended buying shares of Wockhardt, TFCI, and HBL Engineering today

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

In the March quarter (Q4FY26), Wockhardt posted net profit year-on-year (Y-o-Y) of ₹166 crore, as compared to a net loss of ₹25 crore a year ago

The Indian equity market was trading sharply higher, driven by hopes of de-escalation in the war between US-Israel and Iran

The company said the United States Food and Drug Administration (USFDA) has formally accepted the New Drug Application (NDA) for its first-in-class antibiotic 'Zaynich'

Ten out of Nifty 500 stocks declined up to 23% in October even as the Nifty and Nifty 500 gained around 4.5% each; should you buy these stocks or sell? Here's what the technical charts suggest.

Drug firm Wockhardt on Wednesday said it has submitted a new drug application for its novel antibacterial drug with the US health regulator. The company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (USFDA) for its novel antibacterial agent Zidebactam-Cefepime injection, the Mumbai-based drugmaker said in a regulatory filing. The NDA seeks approval for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with or without concurrent bacteremia caused by Gram-negative bacteria, including multidrug-resistant (MDR), it added. In the US and EU, more than 8 million cases of cUTI are reported every year, reflecting the global burden of Gram-negative infections, the drug firm stated. "This milestone marks the first-ever NDA submission to the US FDA for a drug, fully discovered and developed by an Indian pharmaceutical company, a momentous achievement for Indian innovation," Wockhardt Ltd said. The NDA submission follows

Thus far in the calendar year 2025, the BSE smallcap index has underperformed the market by falling 5%, as against 3% decline in midcap index and 3% rise in the BSE Sensex.

Shukra Pharmaceuticals on Wednesday said it has entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd. The authorization is effective from September 9, 2025 and is valid until March 2026, an exchange filing said. The products include advanced anti-infective formulations and antibiotics developed to combat critical infections. The mandate includes distribution and management of products across all ESIC/ESIS hospitals and Defence/AFMSD/DGAFMS units throughout India, the filing said. "This collaboration further strengthens Shukra Pharmaceuticals presence in institutional and government healthcare networks across India, enhancing revenue visibility and operational footprint," the company said. Shukra Pharmaceuticals Limited is engaged in manufacturing and marketing pharmaceutical products as well as laboratory testing.

Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses